The Chinese National Institute of Pharmaceutical R&D Co. Ltd. has described sulfonamide compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of diabetes, obesity, cancer, Noonan and LEOPARD syndromes.